Abstract LBA52
Background
ORIENT-15 is a global, randomized, double-blind study to evaluate the efficacy and safety of sintilimab + chemo (S+C) vs chemo (C) as first-line (1L) treatment in patients (pts) with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Methods
Eligible pts were randomized 1:1 to sintilimab/placebo 200 mg Q3W for up to 24 months +chemo (TP: paclitaxel 175 mg/m2 Q3W + cisplatin 75 mg/m2 Q3W or CF: cisplatin 75 mg/m2 Q3W+5-FU 800 mg/m2 on d1-5 Q3W). Randomization was stratified by ECOG PS (0 vs 1), liver metastasis (presence vs absence), chemo regimen (TP vs CF). Treatment continued until progression, unacceptable toxicity or withdrawal. No crossover was permitted. The primary end points were OS in the pts with PD-L1 combined positive score (CPS) ≥10 and all pts. The secondary endpoints were PFS and ORR (RECIST v1.1; by investigator) in the pts with PD-L1 CPS ≥10 and all pts. Data cutoff for interim analysis was Apr 9, 2021.
Results
At data cutoff, 659 pts (86% male, 97% Chinese, 87% metastatic) were randomized (327 S+C, 332 C). Median follow-up was 11.4 months. Sintilimab + chemo vs chemo was superior for OS in all pts (median 16.7 vs 12.5 mo, HR 0.628, 95% CI 0.508-0.777, P < 0.0001) and CPS ≥10 pts (median 17.2 vs 13.6 mo, HR 0.638, 95% CI 0.480-0.848, P =0.0018). PFS was superior with S+C vs C in all pts (median 7.2 vs 5.7 mo, HR 0.558, 95% CI 0.461-0.676, P <0.0001) and CPS ≥10 pts (median 8.3 vs 6.4 mo, HR 0.580, 95% CI 0.449-0.749, P <0.0001). ORR was 75.5 vs 56.9% in all pts, with median DOR of 8.3 vs 5.6 mo. ORR was 78.7 vs 57.5% in CPS ≥10 pts, with median DOR of 8.5 vs 5.5 mo. Of pts receiving at least one drug dose, treatment-related adverse events (TRAEs) rates were 98.2% vs 98.2%. Grade ≥3 TRAEs rates were 59.9% vs 54.5%. Discontinuation rates from TRAEs were 20.8% vs 12.3%. Death rates from TRAEs were 2.8% vs 1.8%.
Conclusions
OS, PFS and ORR are all significantly improved in S+C vs C, with a manageable safety profile in the pts with PD-L1 CPS ≥10 and all pts. Especially the HR of OS is less than 0.7 in all pts. The results demonstrate that the combination of sintilimab and chemo can be considered as a new 1L treatment in patients with advanced or metastatic ESCC.
Clinical trial identification
NCT03748134.
Editorial acknowledgement
Legal entity responsible for the study
Innovent Biologics, Inc., China.
Funding
Innovent Biologics, Inc., China & Eli Lilly and Company, US.
Disclosure
L. Shen: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc.Z. Lu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. J. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Y. Shu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. L. Kong: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. L. Yang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. B. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Z. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Y. Ji: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. G. Cao: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. H. Liu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. T. Cui: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. N. Li: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. W. Qiu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Z. Ma: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. Y. Chen: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. H. Li: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. X. Sun: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc. Y. Wang: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc. H. Zhou: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc.
Resources from the same session
LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Presenter: Jianming Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
Presenter: Alexander Stein
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
Presenter: Eric Van Cutsem
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1373MO - JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Rui-Hua Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA10 - Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
Presenter: Lukas Perkhofer
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA37 - IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)
Presenter: Arndt Vogel
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
Discussion LBA52, LBA53, LBA54 and LBA55
Presenter: Yelena Janjigian
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
Discussion 1373MO, LBA10 and LBA37
Presenter: Changhoon Yoo
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast